分次剂量黄热病疫苗接种的免疫原性与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项试验共2371名参与者,比较分次剂量与标准剂量黄热病疫苗的免疫原性与安全性。接种后4-5周,含标准剂量三分之一至五十分之一的分次剂量组血清转化率与标准剂量组相似,但百分之一及更低分次剂量组血清转化率明显较低。分次与标准剂量接种后免疫原性均可维持8-10年,轻微不良事件无差异,未报告严重不良事件。
要点
- 接种后4-5周,含标准剂量三分之一至五十分之一的分次剂量组血清转化率与标准剂量组相似。
- 含标准剂量百分之一及更低分次剂量组的血清转化率明显低于标准剂量组。
- 分次与标准剂量接种后免疫原性均可维持8-10年,轻微不良事件无差异,未报告严重不良事件。
核心结论
- 研究结果支持将分次剂量接种作为缓解疫苗短缺的策略,该策略应特别考虑用于年轻、免疫功能正常且营养良好的个体。
研究设计与样本
- 系统综述与荟萃分析,在PROSPERO注册(注册号CRD42018084214),方案遵循PRISMA-P,证据合成遵循PRISMA,按疫苗剂量分层进行荟萃分析。
- 从文献检索获得2524条记录,11条可能合格,最终纳入8项合格试验,共2371名参与者。
主要发现
- 接种后4-5周,含标准剂量三分之一的分次剂量组(547名参与者)与标准剂量组血清转化率相似:RR 1.02,95%CI 1.00-1.04。
- 含标准剂量五分之一的分次剂量组(155名参与者)与标准剂量组血清转化率相似:RR 1.00,95%CI 0.98-1.03。
- 含标准剂量十分之一的分次剂量组(890名参与者)与标准剂量组血清转化率相似:RR 0.99,95%CI 0.96-1.01。
- 含标准剂量五十分之一的分次剂量组(661名参与者)与标准剂量组血清转化率相似:RR 0.97,95%CI 0.92-1.02。
- 含标准剂量百分之一及更低分次剂量组的血清转化率明显低于标准剂量组;分次与标准剂量接种后免疫原性均可维持8-10年;轻微不良事件无差异,未报告严重不良事件。
关键数值与推荐
- 接种后4-5周血清转化率:含标准剂量三分之一的分次剂量组 vs 标准剂量组 RR 1.02(95%CI 1.00-1.04)。
- 接种后4-5周血清转化率:含标准剂量五分之一的分次剂量组 vs 标准剂量组 RR 1.00(95%CI 0.98-1.03)。
- 接种后4-5周血清转化率:含标准剂量十分之一的分次剂量组 vs 标准剂量组 RR 0.99(95%CI 0.96-1.01)。
- 接种后4-5周血清转化率:含标准剂量五十分之一的分次剂量组 vs 标准剂量组 RR 0.97(95%CI 0.92-1.02)。
- 含标准剂量百分之一及更低分次剂量组的血清转化率明显低于标准剂量组。
临床怎么用
- 作者认为,研究结果支持将分次剂量接种作为缓解疫苗短缺的策略。
- 作者建议,该策略应特别考虑用于年轻、免疫功能正常且营养良好的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent upsurges in yellow fever outbreaks are increasing the demand for yellow fever vaccine, while enormously straining global vaccine supply. Fractional dose yellow fever vaccination is being considered as a dose-sparing strategy to address current vaccine shortages. This systematic review and meta-analysis aimed to assess the effects of fractional dose yellow fever vaccination, in comparison with those of standard dose vaccination. METHODS: We registered this review on the International Prospective Register of Systematic Reviews (PROSPERO, registration number: CRD42018084214), developed the protocol in line with the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) and synthesised the evidence in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). We stratified meta-analyses by vaccine dose. RESULTS: We retrieved 2524 records from the literature search, eleven of them potentially eligible. From these studies, we included eight eligible trials, with a total of 2371 participants. Seroconversion rates at four to five weeks following vaccination were similar between participants who received standard doses and participants who received fractional doses containing one-third (547 participants: risk ratio [RR] 1.02, 95% confidence interval [CI] 1.00-1.04), one-fifth (155 participants: RR 1.00, 95% CI 0.98-1.03), one-tenth (890 participants: RR 0.99, 95% CI 0.96-1.01), and one-fiftieth (661 participants: RR 0.97, 95% CI 0.92-1.02) of the standard dose. However, the rates of seroconversion were substantially lower among participants who received fractional doses containing one-hundredth and lower fractions of the standard dose. Immunogenicity similarly persisted 8-10 years following both fractional and standard dose vaccination. Minor adverse events following vaccination did not differ across doses, and no serious adverse events were reported in any study arm. CONCLUSIONS: These findings support the use of fractional dosing as a strategy for mitigating vaccine shortages. The strategy should be specifically considered for individuals who are young, immuno-competent and well nourished.
引用
- Nnaji CA, Shey MS, Adetokunboh OO, et al. Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis. Vaccine. 2019. PMID: 31859201. doi:10.1016/j.vaccine.2019.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。